Journal of Clinical Virology - Volume 82 - Supplement 1 - September 2016

90 / 152

S86 Abstracts / Journal of Clinical Virology 82S (2016) S1–S142
study is the first multicentre study to reflect the HBV vaccination
rates among laboratory workers across the entire country. Accord-
ing to the findings obtained from this study, it was understood that
approximately one third of the laboratory staff was vulnerable to
hepatitis B virus infections, which were protectable. As a result,
medical laboratory personnel possess the risk of acquiring hep-
atitis B infection, so that formation of awareness is necessary by
way of education. They should be tested and all staff seronegative
staff should be vaccinated. Periodic monitoring for anti-HBs levels
is also essential. This assessment is a necessity within the scope of
infection control measures, workers ´health and safety
Keywords: Hepatitis B virus, Surveys and questionnaires, Labo-
ratory personnel, Vaccination
Reference
[1] World Health Organization. Health Care Worker Safety. AIDE-MEMOIRE for a
Strategy to Protect Health Workers from Infection with Bloodborne Viruses.
[2]
[3] Z. Karacaer, I.I. Ozturk, H. Cicek, S. Simsek, G. Duran, L. Gorenek, The level of
information about the immunization of health care workers, attitudes and
behaviors (Saglık c¸ alıs¸ anlarının ba˘gıs¸ ıklanma ile ilgili bilgi düzeyleri, tutum ve
davranıs¸ ları), TAF Prev. Med. Bull. 14 (5) (2015).
Abstract no: 110
Presentation at ESCV 2016: Poster 131
Treatment of HIV and acute myeloid leukemia
by allogeneic CCR5-d32 blood stem cell
transplantation
E. Knops ∗, G. Kobbe , R. Kaiser , N. Luebke ,
G. Dunay , J. Fischer , F. Huettig , A. Wensing ,
R. Haas , M. Nijhuis , J. Martinez-Picado ,
D. Haeussinger , B. Jensen
1 University of Cologne, Germany
2 University of Duesseldorf, Germany
3 Leibniz Institute for Experimental Virology,
Hamburg, Germany
4 Medical Center Utrecht, Netherlands
5 AIDS Research Institute irsiCaixa, Barcelona, Spain
The Berlin patient is presumed to be the only person cured from
HIV-infection by hematopoietic stem cell transplantation (HSCT)
from a homozygous CCR5-d32 donor. Attempts to reproduce cure
by HSCT have failed because of either viral rebound or death due
to the underlying malignancy. We here report a patient alive, well
and negative for proviral DNA 900 days after HSCT.
A 41 year old HIV-infected male patient was diagnosed acute
myeloid leukemia (AML, inv16, CBF-MYH11) in 01/2011. Since
the diagnosis of HIV-infection in 10/2010 he had been treated
with TDF/FTC+ DRV (01/2011 VL 44 cop/mL; CD4+ 474 cells/ l). To
avoid interactions with chemotherapy DRV was switched to RAL
in 03/2011. He achieved CR of the AML after 1 induction course
(ICE) and received a 2nd induction and 3 consolidation courses
according to AML-SG 07/04. In 09/2012 AML relapsed and he was
treated with A-HAM and a 2nd cycle high-dose cytarabine. While
in 2nd CR he received unmodified peripheral blood stem cells from
a female 10/10 CCR5-d32 DKMS-donor after conditioning with flu-
darabine/treosulfan in 02/2013. Before transplant HIV resistance
analysis was performed and viral tropism was determined. There
were no significant resistance mutations and the coreceptor-usage
was predicted as R5-tropic (Sanger sequencing: FPR 44.5%; NGS:
0.14% X4 at 3.5% FPR; geno2pheno). The proviral DNA load was
29400 cop/mL and in the western blot all anticipated bands could
be detected. During transplant and until today the patient remained
on ART (since 06/2014 ABC/3TC/DTG) and the viral load remained
undetectable in plasma and liquor. He had a 2nd relapse of AML
in 06/2013 but re-entered molecular remission after a total of 8
courses of 5-azacytidine and 4 donor lymphocyte infusions. Con-
cerningHIV, all collected sampleswere negative for proviral DNAby
conventional and digital droplet PCR* in two different labs, namely
PBMCs (06/2014, 01/2015* and 02/2015), rectal biopsy (04/2015)
and bone marrow (08/2015*). Western blots from 06/2014 and
02/2015 showed incomplete patterns with fading bands.
Like in the Berlin patient, all tests from the Duesseldorf patient
so far suggest that HIV may have been eradicated and that he may
be the second individual cured from HIV by allogeneic CCR5-d32
HSCT. Further investigations will be performed before considering
the discontinuation of ART.
Abstract no: 119
Presentation at ESCV 2016: Poster 132
Evaluation of the Aptima HIV-1 Quant Dx Assay
using plasma and dried blood spots
M. Sahoo ∗, V. Varghese, E. White, Meg Winslow,
D. Katzenstein, R. Shafer, B. Pinsky
Stanford University School of Medicine, Stanford, CA,
USA
HIV-1 RNA quantitation in plasma, or virus load testing, is
the primary method by which the response to antiretroviral
therapy is monitored. In the current study, we describe the ana-
lytical and clinical evaluation of the Aptima® HIV-1 Quant Dx
assay (Aptima) performed on the automated Panther® system.
Using HIV-1 subtype B, Aptima had a dynamic range extending
from 6.7 to 2.0 log 10 copies/mL, the lower limit of 95% detec-
tion was <20 copies/mL, and within-laboratory precision at low
virus loads ranged from percent coefficient of variation (CV) of
8.13% at 1.7 log 10 copies/mL to 3.59% at 3.0 log10 copies/mL. The
clinical performance of Aptima was compared to the COBAS®
AmpliPrep/COBAS® TaqMan® HIV-1 Test v2.0 (CAP/CTM) using
162 EDTA plasma samples collected from patients undergoing
HIV-1 monitoring. Overall agreement was 84.0% (136/162) with a
kappa statistic of 0.723 (Standard Error 0.047; 95% CI 0.630–0.815)
indicating substantial agreement. Using the 86 clinical sam-
ples quantifiable by both methods, Passing-Bablok regression
revealed a regression line of Y = 1.069X −0.346 [95% CI of the slope
(1.003–1.139) and intercept (−0.666 to −0.074)] and Bland–Altman
analysis demonstrated a mean difference (Aptima-CAP/CTM) of
−0.075 log10 copies/mL (95% limits of agreement of −0.624 to
0.475), consistent with negative bias. Comparison of Aptima testing
on paired dried blood spot (DBS) and plasma specimens archived
from participants in the Peninsula AIDS Research Cohort Study
(PARC) demonstrated an overall agreement of 94.7% (90/95) when
1000 copies/mL was used as threshold. In conclusion, the Aptima
HIV-1 Quant Dx assay provides a suitable alternative for HIV-1
monitoring in plasma and DBS.